EUVIMEDOpdag EUVIMED
KohortenstudieOpen access

Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study

Hideaki L Tanaka iD, Judy R Rees iD, Ziyin Zhang iD, Judy A Ptak iD, Pamela M Hannigan iD, Elaine M Silverman iD, Janet L Peacock iD, Jay C Buckey iD, Multicenter Registry for Hyperbaric Oxygen Treatment Consortium

Interactive Journal of Medical Research · 2024-08-20 · 13 · e53821

DOI: 10.2196/53821 ↗

At a glance

Kohortenstudie in Interactive Journal of Medical Research, published online on 2024-08-20. Written by Hideaki L Tanaka and 8 co-authors. Institution: Division of Undersea and Hyperbaric Medicine, Department of Emergency Medicine, University of California at San Diego, San Diego, CA, United States. Cited 10 times so far (Crossref); 56 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Hyperbaric oxygen (HBO2) treatment is used across a range of medical specialties for a variety of applications, particularly where hypoxia and inflammation are important contributors. Because of its hypoxia-relieving and anti-inflammatory effects HBO2 may be useful for new indications not currently approved by the Undersea and Hyperbaric Medical Society. Identifying these new applications for HBO2 is difficult because individual centers may only treat a few cases and not track the outcomes consistently. The web-based International Multicenter Registry for Hyperbaric Oxygen Therapy captures prospective outcome data for patients treated with HBO2 therapy. These data can then be used to identify new potential applications for HBO2, which has relevance for a range of medical specialties.

Objective

Although hyperbaric medicine has established indications, new ones continue to emerge. One objective of this registry study was to identify cases where HBO2 has been used for conditions falling outside of current Undersea and Hyperbaric Medical Society–approved indications and present outcome data for them.

Methods

This descriptive study used data from a web-based, multicenter, international registry of patients treated with HBO2. Participating centers agree to collect data on all patients treated using standard outcome measures, and individual centers send deidentified data to the central registry. HBO2 treatment programs in the United States, the United Kingdom, and Australia participate. Demographic, outcome, complication, and treatment data, including pre- and posttreatment quality of life questionnaires (EQ-5D-5L) were collected for individuals referred for HBO2 treatment.

Results

Out of 9726 patient entries, 378 (3.89%) individuals were treated for 45 emerging indications. Post–COVID-19 condition (PCC; also known as postacute sequelae of COVID-19; 149/378, 39.4%), ulcerative colitis (47/378, 12.4%), and Crohn disease (40/378, 10.6%) accounted for 62.4% (n=236) of the total cases. Calciphylaxis (20/378, 5.3%), frostbite (18/378, 4.8%), and peripheral vascular disease–related wounds (12/378, 3.2%) accounted for a further 13.2% (n=50). Patients with PCC reported significant improvement on the Neurobehavioral Symptom Inventory (NSI score: pretreatment=30.6; posttreatment=14.4; P

Subjects

Author keywords

PASCPCCcalciphylaxisfacial fillerfrostbitehyperbaric oxygenhypospadiasinfected implanted hardwareinflammatory bowel diseasepostacute sequelae of COVID-19post–COVID-19 conditionpyoderma gangrenosum

Authors and institutions

  • Division of Undersea and Hyperbaric Medicine, Department of Emergency Medicine, University of California at San Diego, San Diego, CA, United States.
  • Geisel School of Medicine, Dartmouth College, Lebanon, NH, United States.
  • Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.
  • see Acknowledgments, .

ORCID profiles: Hideaki L Tanaka, Judy R Rees, Ziyin Zhang, Judy A Ptak, Pamela M Hannigan, Elaine M Silverman, Janet L Peacock, Jay C Buckey

Cite

APA

Tanaka, H. L., Rees, J. R., Zhang, Z., Ptak, J. A., Hannigan, P. M., Silverman, E. M., Peacock, J. L., Buckey, J. C., & Multicenter Registry for Hyperbaric Oxygen Treatment Consortium (2024). Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study. Interactive Journal of Medical Research, 13, e53821. https://doi.org/10.2196/53821

Vancouver

Tanaka HL, Rees JR, Zhang Z, Ptak JA, Hannigan PM, Silverman EM, et al. Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study. Interactive Journal of Medical Research. 2024;13:e53821. doi:10.2196/53821

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Hideaki L and Rees, Judy R and Zhang, Ziyin and Ptak, Judy A and Hannigan, Pamela M and Silverman, Elaine M and Peacock, Janet L and Buckey, Jay C and Multicenter Registry for Hyperbaric Oxygen Treatment Consortium, Multicenter Registry for Hyperbaric Oxygen Treatment Consortium},
  title = {Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study},
  journal = {Interactive Journal of Medical Research},
  year = {2024},
  volume = {13},
  pages = {e53821},
  doi = {10.2196/53821}
}
Start for free →